Evidence map›Paper›PMID 42285094›Full record

ArticleCell reports. Medicine2026

Subretinal rAAV2-based VEGF-Trap gene therapy for neovascular age-related macular degeneration: Preclinical assessment and phase 1 trial results.

Tong Li, Jingyang Feng, Xiaolu Yang, Shiqi Yang, Jieqiong Chen, Yidong Wu, Xiaosa Li, Zhuoyu Ni, Yang Liu, Minlu Song and 8 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Tong LiDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Gene Therapy Center, Shanghai, China; Shanghai Key Clinical Specialty, Shanghai, China; Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China.
Jingyang FengDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Gene Therapy Center, Shanghai, China; Shanghai Key Clinical Specialty, Shanghai, China.
Xiaolu YangDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Gene Therapy Center, Shanghai, China; Shanghai Key Clinical Specialty, Shanghai, China.
Shiqi YangDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Gene Therapy Center, Shanghai, China; Shanghai Key Clinical Specialty, Shanghai, China.
Jieqiong ChenDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Gene Therapy Center, Shanghai, China; Shanghai Key Clinical Specialty, Shanghai, China.
Yidong WuDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Gene Therapy Center, Shanghai, China; Shanghai Key Clinical Specialty, Shanghai, China.
Xiaosa LiDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Gene Therapy Center, Shanghai, China; Shanghai Key Clinical Specialty, Shanghai, China; Shanghai Key Laboratory of Ocular Fundus Disease, Shanghai, China.
Zhuoyu NiInnostellar Biotherapeutics Co., Ltd, Shanghai, China.
Yang LiuInnostellar Biotherapeutics Co., Ltd, Shanghai, China.
Minlu SongInnostellar Biotherapeutics Co., Ltd, Shanghai, China.
Peirong HuangDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Gene Therapy Center, Shanghai, China; Shanghai Key Clinical Specialty, Shanghai, China.
Kairong ZhengDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Key Clinical Specialty, Shanghai, China.
Hong WangDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Gene Therapy Center, Shanghai, China; Shanghai Key Clinical Specialty, Shanghai, China.
Xian XuDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Gene Therapy Center, Shanghai, China; Shanghai Key Clinical Specialty, Shanghai, China.
Junran SunDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Gene Therapy Center, Shanghai, China; Shanghai Key Clinical Specialty, Shanghai, China; Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China.
Fenghua WangInnostellar Biotherapeutics Co., Ltd, Shanghai, China. Electronic address: wangfenghua@innostellarbio.com.
Huixun JiaDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Gene Therapy Center, Shanghai, China; Shanghai Key Clinical Specialty, Shanghai, China; Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China. Electronic address: jiahuixun@stju.edu.cn.
Xiaodong SunDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; National Clinical Research Center for Eye Diseases, Shanghai, China; Shanghai Gene Therapy Center, Shanghai, China; Shanghai Key Clinical Specialty, Shanghai, China; Shanghai Key Laboratory of Ocular Fundus Disease, Shanghai, China; Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China. Electronic address: xdsun@sjtu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intraocular vascular endothelial growth factor (VEGF) antagonists for neovascular age-related macular degeneration (nAMD) require frequent injections, leading to treatment burden and suboptimal outcomes. LX102 is an rAAV2-based gene therapy encoding VEGF-Trap via subretinal delivery. In laser-induced choroidal neovascularization (CNV) mouse models, LX102 prevents lesion formation and progression in a dose-dependent manner. In non-human primates, a single LX102 injection reduces grade IV CNV lesions by over 85% and maintains transgene expression for 26 weeks without drug-related ocular abnormalities. In a phase 1 dose-escalation study, 12 participants with nAMD receive a single LX102 administration (2 × 10

Indexed as

Choroidal NeovascularizationDependovirusGenetic TherapyMacular DegenerationVascular Endothelial Growth Factor AAgedAged, 80 and overAnimalsFemaleGene Therapy AgentsGenetic VectorsHumansMaleMiceMiddle AgedRetinaVascular Endothelial Growth Factor Aanti-VEGFgene therapyLX102neovascular age-related macular degenerationsubretinal injection

Identifiers

PMID42285094
PMCPMC13400169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.